PCI Pharma Services submitted a notification on November 21, 2024, to the Foreign-Trade Zones (FTZ) Board about proposed production activities at their facilities in Croydon and Philadelphia, Pennsylvania. The notification followed FTZ Board regulations, and public comments were invited through a notice in the Federal Register on November 29, 2024. By March 21, 2025, the FTZ Board decided that no further review was needed, and authorized the production activity as per the FTZ Act and regulations.
Simple Explanation
PCI Pharma Services, a company in Pennsylvania, got permission to make medicines in special areas called Foreign-Trade Zones, which helps them do this more easily and cheaply. The permission was given after making sure everything was okay and letting people share their thoughts.